ETHMOZINE
LOE ApproachingNDAORALTABLETPriority Review
Approved
Jun 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ETHMOZINE is an oral small-molecule tablet approved in 1990 by Takeda for an undisclosed indication. The mechanism of action and pharmacologic class are not publicly detailed in available data.
LOE Approaching
As ETHMOZINE approaches loss of exclusivity, the brand team is likely consolidating, with focus shifting to lifecycle management and transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ETHMOZINE currently shows zero linked job openings, reflecting its mature, LOE-approaching lifecycle. Roles on this product are primarily defensive and operationally focused, with limited exposure to innovation or strategic growth projects.
Brand ManagerProduct Manager
Worked on ETHMOZINE at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.